PRINCETON, N.J., March 19 Derma Sciences, Inc. (Nasdaq: DSCI), a specialty medical device/pharmaceutical company focused on advanced wound care, will present at the RedChip New York Equities Growth Conference on March 23, 2010 at 2:30 pm EDT. The event will be held at the NASDAQ Market Site in New York City's Times Square. Edward J. Quilty, CEO of Derma Sciences will provide attendees with an overview of the company's business operations and investment highlights.
Advertisement
Over 25 emerging growth companies will deliver financial presentations during the March 23-24 conference. The participating companies represent a wide range of sectors including Biotechnology, Healthcare, Education, Oil & Gas, Basic Materials, Consumer Goods, Alternative Energy, Precious Metals Mining, and more. Additional information regarding the conference can be found at http://www.redchip.com/visibility/conferencePages/NewYorkMar2010/conferenceMain.asp.
Advertisement
About Derma Sciences, Inc.
Derma Sciences is a global manufacturer and marketer of advanced wound care products. Its key product, MEDIHONEY®, is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale randomized controlled trial on leg ulcers. Other key novel products introduced into the $14 billion global wound care market include XTRASORB(TM) for better management of wound exudate, and BIOGUARD(TM) for infection prevention. Derma also has in development DSC127, a novel pharmaceutical for accelerated wound healing and scar reduction. DSC127, an angiotensin analog, has shown positive healing results in multiple pre-clinical animal models. One possible mode of action of the drug is the up-regulation of mesenchymal stem cells at the wound site. Derma expects to announce the key efficacy endpoint result from this study during Q3 of 2010.
For more information about Derma Sciences, Inc., visit http://www.dermasciences.com.
Contact: Derma Sciences, Inc. John E. Yetter Vice President and CFO [email protected] (609) 514- 4744 The Investor Relations Group 212-825-3210 Jason Strominger (Investor Relations) Janet Vasquez (Media Relations)
SOURCE Derma Sciences, Inc.
